Abstract
Influenza virus is a continuous and severe global threat to mankind. The continuously re-emerging disease gives rise to thousands of deaths and enormous economic losses each year, which emphasizes the urgency and necessity to develop high-quality influenza vaccines in a safer, more efficient and economic way. The influenza subunit and VLP vaccines, taking the advantage of recombinant DNA technologies and expression system platforms, can be produced in such an ideal way. This review summarized the recent advancements in the research and development of influenza subunit and VLP vaccines based on the recombinant expression of hemagglutinin antigen (HA), neuraminidase antigen (NA), Matrix 2 protein (M2) and nucleocapsid protein (NP). It would help to get insight into the current stage of influenza vaccines, and suggest the future design and development of novel influenza vaccines.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Altstein A D, Gitelman A K, Smirnov Y A, et al. 2006. Immunization with influenza a np-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol, 151(5): 921–931.
Barefoot B E, Sample C J, Ramsburg E A. 2009. Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces cd8 t-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus. Clin Vaccine Immunol, 16(4): 488–498.
Biesova Z, Miller M A, Schneerson R, et al. 2009. Preparation, characterization, and immunogenicity in mice of a recombinant influenza h5 hemagglutinin vaccine against the avian h5n1 a/vietnam/1203/2004 influenza virus. Vaccine, 27(44): 6234–6238.
Brands R, Visser J, Medema J, et al. 1999. Influvac: A safe madin darby canine kidney (mdck) cell culture-based influenza vaccine. Dev Biol Stand, 98: 93–100; discussion 111.
Brett I C, Johansson B E. 2005. Immunization against influenza a virus: Comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology, 339(2): 273–280.
Chen B J, Leser G P, Morita E, et al. 2007. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol, 81(13): 7111–7123.
Couch R B, Cate T R. 1983. Managing influenza in older patients. Geriatrics, 38(9): 61–74.
Cox M M. 2005. Cell-based protein vaccines for influenza. Curr Opin Mol Ther, 7(1): 24–29.
Cox M M, Hollister J R. 2009. Flublok, a next generation influenza vaccine manufactured in insect cells. Biologicals, 37(3): 182–189.
Cox M M, Patriarca P A, Treanor J. 2008. Flublok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi Viruses, 2(6): 211–219.
Cox M M J, Karl Anderson D. 2007. Production of a novel influenza vaccine using insect cells: Protection against drifted strains. Influenza Other Respi Viruses, 1(1): 35–40.
D’Aoust M A, Lavoie P O, Couture M M, et al. 2008. Influenza virus-like particles produced by transient expression in nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J, 6(9): 930–940.
De Filette M, Martens W, Smet A, et al. 2008. Universal influenza a m2e-hbc vaccine protects against disease even in the presence of pre-existing anti-hbc antibodies. Vaccine, 26(51): 6503–6507.
Denis J, Acosta-Ramirez E, Zhao Y, et al. 2008. Development of a universal influenza a vaccine based on the m2e peptide fused to the papaya mosaic virus (papmv) vaccine platform. Vaccine, 26(27): 3395–3403.
Doherty P C, Turner S J, Webby R G, et al. 2006. Influenza and the challenge for immunology. Nat Immunol, 7(5): 449–455.
Fiers W, De Filette M, Birkett A, et al. 2004. A “universal” human influenza a vaccine. Virus Res, 103(1–2): 173–176.
Gavrilov V, Orekov T, Alabanza C, et al. 2011. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: Validation of a neuraminidase neutralizing antibody assay. J Virol Methods, 173(2): 364–373.
Gerdil C. 2003. The annual production cycle for influenza vaccine. Vaccine, 21(16): 1776–1779.
Govorkova E A, Leneva I A, Goloubeva O G, et al. 2001. Comparison of efficacies of rwj-270201, zanamivir, and oseltamivir against h5n1, h9n2, and other avian influenza viruses. Antimicrob agents ch, 45(10): 2723–2732.
Grandea A G, Olsen O A, Cox T C, et al. 2010. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza a viruses. Proc Natl Acad Sci USA, 107(28): 12658–12663.
Holmes E C, Ghedin E, Miller N, et al. 2005. Whole-genome analysis of human influenza a virus reveals multiple persistent lineages and reassortment among recent h3n2 viruses. Plos Biology, 3(9): e300.
Holsinger L J, Alams R. 1991. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology, 183(1): 32–43.
Holtz K M, Anderson D K, Cox M M J. 2003. Production of a recombinant influenza vaccine using the baculovirus expression vector system. Bioprocess J, 2: 25–32.
Bac-to-bac® baculovirus expression system. 2010. An efficient site-specific transposition system to generate baculovirus for high-level expression of recombinant proteins. Invitrogen. p1–69.
Johansson B, Kilbourne E. 1994. Immunization with purified n1 and n2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition. Proc Natl Acad Sci USA, 91(6): 2358.
Johansson B E, Brett I C. 2007. Changing perspective on immunization against influenza. Vaccine, 25(16): 3062–3065.
Johansson B E, Price P M, Kilbourne E D. 1995. Immunogenicity of influenza-a virus n2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine, 13(9): 841–845.
Johansson B E, Pokorny B A, Tiso V A. 2002. Supplementation of conventional trivalent influenza vaccine with purified viral n1 and n2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine, 20(11–12): 1670–1674.
Khurana S, Wu J, Verma N, et al. 2011. H5n1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol, 85(21): 10945–10954.
Kilbourne E D, Cerini C, Khan M, et al. 1987. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J Immunol, 138(9): 3010.
Kilbourne E D, Pokorny B A, Johansson B, et al. 2004. Protection of mice with recombinant influenza virus neuraminidase. J Infect Dis, 189(3): 459–461.
Lamb R, Krug R. 2001. Orthomyxoviridae: The viruses and their replication. In: Fields Virology. Knipe D N, Howley P M, Griffin D E, et al, ed. Philadelphia: Lippincott Williams and Wilkins Publishers, pp1487–1532.
Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, et al. 2011. Safety and immunogenicity of a virus-like particle pandemic influenza a (h1n1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in mexico. Vaccine, doi:10.1016/j.vaccine.2011.07.099.
Mahmood K, Bright R A, Mytle N, et al. 2008. H5n1 vlp vaccine induced protection in ferrets against lethal challenge with highly pathogenic h5n1 influenza viruses. Vaccine, 26(42): 5393–5399.
McKimm-Breschkin J, Trivedi T, Hampson A, et al. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Ch, 47(7): 2264–2272.
Mena I, Jambrina E, Albo C, et al. 1999. Mutational analysis of influenza a virus nucleoprotein: Identification of mutations that affect rna replication. J Virol, 73(2): 1186–1194.
Murphy B R, Kasel J A, Chanock R M. 1972. Association of serum anti-neuraminidase antibody with resistance to influenza in man. New Engl J Med, 286(25): 1329–1332.
Neumann G, Noda T, Kawaoka Y. 2009. Emergence and pandemic potential of swine-origin h1n1 influenza virus. Nature, 459(7249): 931–939.
Pau M G, Ophorst C, Koldijk M H, et al. 2001. The human cell line per.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine, 19(17–19): 2716–2721.
Pinto L H, Lamb R A. 2006. The m2 proton channels of influenza a and b viruses. J Biol Chem, 281(14): 8997–9000.
Pleschka S, Ludwig S, Wolff T, et al. 2006. Anti-viral approaches against influenza viruses. New Concepts of Antiviral Therapy, 115–167.
QIAexpressionist A. 2002. A handbook for high-level expression and purification of 6xhis-tagged proteins. Qiagen. p1–125.
Quan F S, Huang C, Compans R W, et al. 2007. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol, 81(7): 3514–3524.
Roldao A, Mellado M C, Castilho L R, et al. 2010. Virus-like particles in vaccine development. Expert Rev Vaccines, 9(10): 1149–1176.
Schotsaert M, De Filette M, Fiers W, et al. 2009. Universal m2 ectodomain-based influenza a vaccines: Preclinical and clinical developments. Expert Rev Vaccines, 8(4): 499–508.
Sylte M J, Suarez D L. 2009. Influenza neuraminidase as a vaccine antigen. In:Vaccines for Pandemic Influenza. Compans R W, Orenstein W A, eds. Heidelberg: Springer, p227–241.
Szecsi J, Boson B, Johnsson P, et al. 2006. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic h5n1 and h7n1 influenza viruses. Virol J, 3: 70.
Treanor J J, Schiff G M, Hayden F G, et al. 2007. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: A randomized controlled trial. JAMA, 297(14): 1577–1582.
Wang K, Holtz K M, Anderson K, et al. 2006. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine, 24(12): 2176–2185.
Wang R, Song A, Levin J, et al. 2008. Therapeutic potential of a fully human monoclonal antibody against influenza a virus m2 protein. Antiviral Res, 80(2): 168–177.
Webster R G, Bean W J, Gorman O T, et al. 1992. Evolution and ecology of influenza-a viruses. Microbiol Rev, 56(1): 152–179.
Weldon W C, Wang B Z, Martin M P, et al. 2010. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One, 5(9).
Wu C Y, Yeh Y C, Yang Y C, et al. 2010. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One, 5(3): e9784.
Youil R, Su Q, Toner T J, et al. 2004. Comparative study of influenza virus replication in vero and mdck cell lines. J Virol Methods, 120(1): 23–31.
Author information
Authors and Affiliations
Corresponding author
Additional information
Foundation items: The Knowledge Innovation Program of the Chinese Academy of Sciences (Grant No. KSCX2-EW-G-8).
Rights and permissions
About this article
Cite this article
Deng, Mp., Hu, Zh., Wang, Hl. et al. Developments of subunit and VLP vaccines against influenza a virus. Virol. Sin. 27, 145–153 (2012). https://doi.org/10.1007/s12250-012-3241-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12250-012-3241-1